Cecilia López-Valdivia

Dr. Cecilia López-Valdivia

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAlfonso García Piñero
Alfonso García Piñero
TPTomas Pérez-Carbonell
Tomas Pérez-Carbonell
MGMaría-José Gómez-Gómez
María-José Gómez-Gómez
EDEncarna Domenech-Campos
Encarna Domenech-Campos
FMFernando Martinez-Expósito
Fernando Martinez-Expósito
Miguel ArmengotMiguel Armengot
Miguel Armengot
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic upper airway disease that may involve different inflammatory endotypes, although in Western populations it is most commonly associated with type 2 inflammation. CRSwNP has a significant impact on the patient’s quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms in many patients; however, a subset continues to exhibit persistent type 2 inflammation, evidenced by recurrent nasal polyps, elevated eosinophil counts, or the need for systemic corticosteroids or surgery. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real-world settings in a diverse patient population, focusing on assessing the impact of this therapy on patient-reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in the nasal polyp score (NPS) was the main clinical endpoint. Changes in the Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogue scale scores, and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: In total, 47 patients were included, and 91% were asthmatic. The nasal polyp score (0–8) was reduced significantly in the cohort (mean change: −2.56, p < 0.0001). The mean SNOT-22 score improved 25.29 points. Nasal congestion (−3.57, p < 0.0001) and smell impairment (−4.0, p < 0.0001) visual analog scale scores (0–10) showed a significant improvement. Blood and tissue eosinophil median counts showed significant reductions versus baseline of 86% and 26%, respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusions: This study provides real-world evidence supporting the effectiveness of mepolizumab in managing CRSwNP in patients with features suggestive of type 2 inflammation. The observed improvements in patient-reported outcomes, nasal polyp burden, and asthma control suggest that mepolizumab may be a valuable therapeutic option for this patient population.

1 January 2020 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
Tommaso GiulianiTommaso Giuliani
Tommaso Giuliani
MRMaria López Rubio
Maria López Rubio
EMEva María Montalvá
Eva María Montalvá
JIJavier Maupoey Ibañez
Javier Maupoey Ibañez
ARAndrea Boscá Robledo
Andrea Boscá Robledo
RARafael Lopez Andujar
Rafael Lopez Andujar
Giuliani T, et al. Ann Hepatobiliary Pancreat Surg. 2020 Feb;24(1):90-96. https://doi.org/10.14701/ahbps.2020.24.1.90

21 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlfonso García Piñero
Alfonso García Piñero
TPTomas Pérez-Carbonell
Tomas Pérez-Carbonell
MGMaría-José Gómez-Gómez
María-José Gómez-Gómez
EDEncarna Domenech-Campos
Encarna Domenech-Campos
FMFernando Martínez-Expósito
Fernando Martínez-Expósito
Miguel ArmengotMiguel Armengot
Miguel Armengot
Background: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a type-2 inflammatory upper respiratory disease that has a significant impact on the patient's quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms, but some patients are unable to control inflammation. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real life settings in a diverse patient population, focusing on assessing the impact of this therapy on patient reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in nasal polyp score (NPS) was the main clinical endpoint. Changes in Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogical scales and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: 47 patients were included. 91% were asthmatic. The nasal polyp score (0-8) was reduced significantly in the cohort (mean change: -2.56, p 0.0001). Mean SNOT-22 score improved 25.29 points. Nasal congestion (-3.57, p<0.0001) and smell impairment (-4.0, p<0.0001) visual analogical scales (0 -10) showed a significant improvement. Blood and tissue eosinophil median counts showed a significant reduction versus baseline of 86% and 26% respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusion: This study provides compelling evidence for the effectiveness of mepolizumab in managing recalcitrant CRSwNP in a real-world setting.